Abbott Laboratories Stocks

$ 108.27Last Updated 27.01.2026

Issuer Rating

6/7

Performance

Average

Risk

Low

Recommendation

Buy

Market Cap

$ 186.83B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
News
$ 108.27
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive...

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of ABT is 145 and suggests 35% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks